The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network.
Mohammad Sharif HossainRobert J CommonsNicholas M DouglasKamala ThriemerBereket H AlemayehuChanaki AmaratungaAnupkumar R AnvikarElizabeth A AshleyPuji B S AsihVerena Ilona CarraraChanthap LonUmberto D AlessandroTimothy M E DavisArjen M DondorpMichael D EdsteinRick M FairhurstMarcelo Urbano FerreiraJimee HwangBart JanssensHarin KarunajeewaJean R KiechelSimone Ladeia-AndradeMoses LamanMayfong MayxayRose McGreadyBrioni R MooreIvo MuellerPaul N NewtonThuy-Nhien NguyenHarald NoedlFrancois H NostenAung Pyae PhyoJeanne Rini PoespoprodjoDavid L SaundersFrank M SmithuisMichele D SpringKasia StepniewskaSeila SuonYupin SuputtamongkolDin SyafruddinHien T TranNeena ValechaMichel Van HerpMichele Van VugtNicholas J WhitePhilippe J GuerinJulie Anne SimpsonRichard N PricePublished in: PLoS medicine (2020)
In this meta-analysis, we found a high risk of P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between studies. These P. vivax infections are likely attributable to relapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the benefits of such a novel strategy will vary considerably between geographical areas.